Deparment of Health Service Research, School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK.
Clinical Trials Research Unit (CTRU), ScHARR, The University of Sheffield, Sheffield, UK.
Lancet Neurol. 2019 Sep;18(9):821-833. doi: 10.1016/S1474-4422(19)30192-9.
Post-stroke aphasia might improve over many years with speech and language therapy; however speech and language therapy is often less readily available beyond a few months after stroke. We assessed self-managed computerised speech and language therapy (CSLT) as a means of providing more therapy than patients can access through usual care alone.
In this pragmatic, superiority, three-arm, individually randomised, single-blind, parallel group trial, patients were recruited from 21 speech and language therapy departments in the UK. Participants were aged 18 years or older and had been diagnosed with aphasia post-stroke at least 4 months before randomisation; they were excluded if they had another premorbid speech and language disorder caused by a neurological deficit other than stroke, required treatment in a language other than English, or if they were currently using computer-based word-finding speech therapy. Participants were randomly assigned (1:1:1) to either 6 months of usual care (usual care group), daily self-managed CSLT plus usual care (CSLT group), or attention control plus usual care (attention control group) with the use of computer-generated stratified blocked randomisation (randomly ordered blocks of sizes three and six, stratified by site and severity of word finding at baseline based on CAT Naming Objects test scores). Only the outcome assessors and trial statistician were masked to the treatment allocation. The speech and language therapists who were doing the outcome assessments were different from those informing participants about which group they were assigned to and from those delivering all interventions. The statistician responsible for generating the randomisation schedule was separate from those doing the analysis. Co-primary outcomes were the change in ability to retrieve personally relevant words in a picture naming test (with 10% mean difference in change considered a priori as clinically meaningful) and the change in functional communication ability measured by masked ratings of video-recorded conversations, with the use of Therapy Outcome Measures (TOMs), between baseline and 6 months after randomisation (with a standardised mean difference in change of 0·45 considered a priori as clinically meaningful). Primary analysis was based on the modified intention-to-treat (mITT) population, which included randomly assigned patients who gave informed consent and excluded those without 6-month outcome measures. Safety analysis included all participants. This trial has been completed and was registered with the ISRCTN, number ISRCTN68798818.
From Oct 20, 2014, to Aug 18, 2016, 818 patients were assessed for eligibility, of which 278 (34%) participants were randomly assigned (101 [36%] to the usual care group; 97 [35%] to the CSLT group; 80 [29%] to the attention control group). 86 patients in the usual care group, 83 in the CSLT group, and 71 in the attention control group contributed to the mITT. Mean word finding improvements were 1·1% (SD 11·2) in the usual care group, 16·4% (15·3) in the CSLT group, and 2·4% (8·8) in the attention control group. Word finding improvement was 16·2% (95% CI 12·7 to 19·6; p<0·0001) higher in the CSLT group than in the usual care group and was 14·4% (10·8 to 18·1) higher than in the attention control group. Mean changes in TOMs were 0·05 (SD 0·59) in the usual care group (n=84), 0·04 (0·58) in the CSLT group (n=81), and 0·10 (0·61) in the attention control group (n=68); the mean difference in change between the CSLT and usual care groups was -0·03 (-0·21 to 0·14; p=0·709) and between the CSLT and attention control groups was -0·01 (-0·20 to 0·18). The incidence of serious adverse events per year were rare with 0·23 events in the usual care group, 0·11 in the CSLT group, and 0·16 in the attention control group. 40 (89%) of 45 serious adverse events were unrelated to trial activity and the remaining five (11%) of 45 serious adverse events were classified as unlikely to be related to trial activity.
CSLT plus usual care resulted in a clinically significant improvement in personally relevant word finding but did not result in an improvement in conversation. Future studies should explore ways to generalise new vocabulary to conversation for patients with chronic aphasia post-stroke.
National Institute for Health Research, Tavistock Trust for Aphasia.
中风后失语症可能在经过言语和语言治疗后多年内逐渐改善;然而,中风后几个月后,言语和语言治疗往往不太容易获得。我们评估了自我管理的计算机化言语和语言治疗(CSLT),作为一种提供比患者仅通过常规护理获得更多治疗的方法。
在这项务实的、优势的、三臂、个体随机、单盲、平行组试验中,参与者从英国 21 个言语和语言治疗部门招募。参与者年龄在 18 岁及以上,在随机分组前至少 4 个月被诊断为中风后失语症;如果他们有其他由中风以外的神经缺陷引起的发病前言语和语言障碍、需要用英语以外的语言进行治疗,或者目前正在使用基于计算机的寻字言语治疗,则将其排除在外。参与者被随机分配(1:1:1)至常规护理(常规护理组)、每日自我管理的 CSLT 加常规护理(CSLT 组)或注意力控制加常规护理(注意力控制组),使用计算机生成的分层区组随机化(随机顺序的大小为三和六的块,基于 CAT 命名物体测试分数,按地点和寻字基线严重程度分层)。只有结局评估者和试验统计学家对治疗分配进行了盲法。进行结局评估的言语和语言治疗师与告知参与者他们被分配到哪个组的治疗师以及提供所有干预措施的治疗师不同。负责生成随机分组计划的统计学家与进行分析的统计学家是分开的。主要结局是图片命名测试中个人相关词汇检索能力的变化(预先设定的变化均值差异为 10%,认为具有临床意义)和视频记录对话的蒙面评估的功能沟通能力的变化,使用治疗结果测量量表(TOMs),在随机分组后 6 个月(预先设定的变化标准化均数差异为 0.45,认为具有临床意义)。主要分析基于修改后的意向治疗(mITT)人群,包括同意并排除无 6 个月结局测量的随机分配患者。安全性分析包括所有参与者。该试验已完成,并在 ISRCTN 注册,编号 ISRCTN68798818。
从 2014 年 10 月 20 日到 2016 年 8 月 18 日,对 818 名患者进行了入选评估,其中 278 名(34%)患者被随机分配(101 名[36%]至常规护理组;97 名[35%]至 CSLT 组;80 名[29%]至注意力控制组)。86 名常规护理组、83 名 CSLT 组和 71 名注意力控制组的患者纳入 mITT。常规护理组的词汇检索改善平均为 1.1%(SD 11.2),CSLT 组为 16.4%(15.3),注意力控制组为 2.4%(8.8)。CSLT 组词汇检索改善比常规护理组高 16.2%(95%CI 12.7 至 19.6;p<0.0001),比注意力控制组高 14.4%(10.8 至 18.1)。常规护理组的 TOMs 变化均值为 0.05(SD 0.59)(n=84),CSLT 组为 0.04(0.58)(n=81),注意力控制组为 0.10(0.61)(n=68);CSLT 组与常规护理组之间的变化差值为-0.03(-0.21 至 0.14;p=0.709),CSLT 组与注意力控制组之间的差值为-0.01(-0.20 至 0.18)。每年严重不良事件的发生率罕见,常规护理组为 0.23 例,CSLT 组为 0.11 例,注意力控制组为 0.16 例。45 例严重不良事件中有 40 例(89%)与试验活动无关,其余 5 例(11%)严重不良事件被归类为不太可能与试验活动有关。
CSLT 加常规护理可显著改善个人相关词汇检索,但对中风后慢性失语症患者的对话无改善。未来的研究应探索将新词汇推广到对话的方法,以帮助患有慢性失语症的中风患者。
英国国家卫生研究院,塔维斯托克信托基金会。